SCHEMBL4034639

SCHEMBL4034639

C=CC[C@@](NC(=O)OCC)(C(=O)O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
TSHR P16473 1/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 2/20 0.40
ATM Q13315 1/20 0.40
HPGD P15428 2/20 0.40
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
THRB P10828 1/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6070276 0.90 KMT2A (0.44) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL6070284 0.85 KDM4E (0.45) ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL9828915 0.84 KDM4E (0.51) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL9828908 0.84 KDM4E (0.51) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL13988283 0.80 KMT2A (0.45) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL9830815 0.76 LMNA (0.45) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL9830821 0.76 LMNA (0.45) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL10444412 0.75 GAA (0.53) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL2278045 0.75 GAA (0.53) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL10440896 0.74 POLB (0.48) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664026-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-01-21 EP disclosed
US-7465746-B2 Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP MERCK & CO., INC. (US) 2008-12-16 US disclosed
US-20080207693-A1 Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-08-28 US disclosed
EP-1861097-A1 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2007-12-05 EP disclosed
US-20070225499-A1 Process for the Preparation of 2,2-Disubstituted Pyrroles MERCK & CO., INC. 2007-09-27 US disclosed
EP-1740537-A2 A PROCESS FOR THE PREPARATION OF 2,2-DISUBSTITUTED PYRROLES Merck & Co., Inc. (US) 2007-01-10 EP disclosed
WO-2006101780-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2006-09-28 WO disclosed
WO-2005102996-A2 A PROCESS FOR THE PREPARATION OF 2,2-DISUBSTITUTED PYRROLES MERCK & CO., INC. (US) 2005-11-03 WO disclosed
US-20050043357-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225499-A1 Process for the Preparation of 2,2-Disubstituted Pyrroles KIF5B, KIF5A, KIF5C ALDH1A1 1475/4885TSHR 4735/4885KMT2A 491/4885
US-20050043357-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B ALDH1A1 2302/4885TSHR 4772/4885KMT2A 431/4885
US-20080207693-A1 Mitotic Kinesin Inhibitors KIF5B, KIF2C, KIF23 ALDH1A1 2547/4885TSHR 4793/4885KMT2A 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.